CY1119084T1 - Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης - Google Patents
Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασηςInfo
- Publication number
- CY1119084T1 CY1119084T1 CY20171100592T CY171100592T CY1119084T1 CY 1119084 T1 CY1119084 T1 CY 1119084T1 CY 20171100592 T CY20171100592 T CY 20171100592T CY 171100592 T CY171100592 T CY 171100592T CY 1119084 T1 CY1119084 T1 CY 1119084T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted tricyclic
- compounds
- disclosed
- tricyclic benzimidazoles
- inhibitors
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Εδώ αποκαλύπτονται ενώσεις υποκατεστημένων τρικυκλικών βενζιμιδαζολίων όπως ορίζονται εδώ στον τύπο (I) ή φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις της εφεύρεσης αναστέλλουν εκλεκτικώς την CDK8 και είναι συνεπώς χρήσιμες για τη θεραπεία νόσων που σχετίζονται με αυτή την κινάση, ειδικότερα ορθοκολικών και μελανωματικών καρκίνων και άλλων στερεών και αιματολογικών κακοηθειών, αυτοάνοσων νόσων και φλεγμονωδών νόσων. Επίσης αποκαλύπτονται διεργασίες για την παρασκευή αυτών των ενώσεων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220157.0A GB201220157D0 (en) | 2012-11-08 | 2012-11-08 | Substitute tricyclic benzimidazoles as kinase inhibitors |
| PCT/EP2013/073311 WO2014072435A1 (en) | 2012-11-08 | 2013-11-07 | Substituted tricyclic benzimidazoles as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119084T1 true CY1119084T1 (el) | 2018-01-10 |
Family
ID=47470315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100592T CY1119084T1 (el) | 2012-11-08 | 2017-06-06 | Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9745299B2 (el) |
| EP (1) | EP2917217B1 (el) |
| JP (1) | JP6101812B2 (el) |
| KR (1) | KR101812390B1 (el) |
| CN (1) | CN104903321B (el) |
| AU (1) | AU2013343550B2 (el) |
| BR (1) | BR112015010019B1 (el) |
| CA (1) | CA2890643C (el) |
| CY (1) | CY1119084T1 (el) |
| DK (1) | DK2917217T3 (el) |
| ES (1) | ES2628046T3 (el) |
| GB (1) | GB201220157D0 (el) |
| HR (1) | HRP20170802T1 (el) |
| HU (1) | HUE033485T2 (el) |
| IL (1) | IL238693A0 (el) |
| LT (1) | LT2917217T (el) |
| MX (1) | MX363609B (el) |
| PL (1) | PL2917217T3 (el) |
| PT (1) | PT2917217T (el) |
| RS (1) | RS56056B1 (el) |
| SI (1) | SI2917217T1 (el) |
| SM (1) | SMT201700291T1 (el) |
| WO (1) | WO2014072435A1 (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015159937A1 (ja) | 2014-04-18 | 2015-10-22 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| CN108348509A (zh) * | 2015-11-03 | 2018-07-31 | Lu许可公司 | 用于治疗增殖减少性病症的化合物 |
| EP3575297B1 (en) | 2017-01-30 | 2024-12-18 | Kyoto University | Novel compound, and method for producing regulatory t cells |
| JPWO2018159805A1 (ja) * | 2017-03-03 | 2020-01-09 | 国立大学法人京都大学 | 膵前駆細胞の製造方法 |
| AU2018249154A1 (en) | 2017-04-03 | 2019-11-21 | Kyoto Pharmaceutical Industries, Ltd. | Novel cyclin-dependent kinase 8 and/or 19 inhibitor |
| US11261184B2 (en) | 2017-10-02 | 2022-03-01 | Boehringer Ingelheim International Gmbh | [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors |
| CN112552314B (zh) * | 2018-08-24 | 2022-03-04 | 杭州阿诺生物医药科技有限公司 | Sting激动剂小分子抗肿瘤化合物及其应用 |
| JP2022511540A (ja) * | 2018-12-14 | 2022-01-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途 |
| CA3156828A1 (en) * | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| CN111349094B (zh) * | 2020-04-23 | 2021-02-02 | 杭州师范大学 | 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用 |
| CN115996917A (zh) | 2020-05-06 | 2023-04-21 | 艾捷斯治疗公司 | 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑 |
| EP4249587A4 (en) | 2020-11-20 | 2025-02-19 | Orizuru Therapeutics Inc | MATURING AGENT |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| CA3208794A1 (en) | 2021-02-09 | 2022-08-18 | Orizuru Therapeutics, Inc. | Maturation agent |
| US20240180921A1 (en) * | 2021-03-25 | 2024-06-06 | University Of South Carolina | Cdk8/19 inhibitors for the treatment of cytokine storm |
| AU2022349176A1 (en) | 2021-09-27 | 2024-04-11 | Kyoto University | Method for producing t cell |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CA3238860A1 (en) | 2021-11-24 | 2023-06-01 | Norihisa MIKAMI | Pharmaceutical composition for treating or preventing t cell-related disorders |
| MX2024006360A (es) | 2021-11-24 | 2024-08-19 | Regcell Co Ltd | Celula t controlable por inducibilidad humana y metodo para prepararla. |
| CN119256076A (zh) | 2022-03-23 | 2025-01-03 | 国立大学法人京都大学 | 用于产生调节性t细胞的方法 |
| WO2023210578A1 (ja) | 2022-04-25 | 2023-11-02 | オリヅルセラピューティクス株式会社 | Ａｌｋ５阻害活性とｃｄｋ８／１９阻害活性とを有する成熟化剤 |
| WO2023241627A1 (en) * | 2022-06-15 | 2023-12-21 | Insilico Medicine Ip Limited | Cdk8/19 dual inhibitors and methods of use thereof |
| CN119546748A (zh) | 2022-07-14 | 2025-02-28 | 千纸鹤治疗公司 | 细胞移植用纤维蛋白凝胶片 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2899757B2 (ja) | 1989-06-26 | 1999-06-02 | 持田製薬株式会社 | ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体 |
| US5500423A (en) * | 1994-09-09 | 1996-03-19 | Hoechst-Roussel Pharmaceuticals Inc. | 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines |
| EA005950B1 (ru) | 2000-08-08 | 2005-08-25 | Санофи-Авентис | Производные бензимидазола, их получение и терапевтическое применение |
| WO2003051879A1 (en) | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| AU2003240742A1 (en) * | 2002-06-07 | 2003-12-22 | Altana Pharma Ag | 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors |
| AU2006279034A1 (en) * | 2005-08-05 | 2007-02-15 | Astrazeneca Ab | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| BRPI0616722A2 (pt) * | 2005-09-30 | 2012-12-25 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| KR20130116358A (ko) * | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
-
2012
- 2012-11-08 GB GBGB1220157.0A patent/GB201220157D0/en not_active Ceased
-
2013
- 2013-11-07 SI SI201330669T patent/SI2917217T1/sl unknown
- 2013-11-07 MX MX2015005772A patent/MX363609B/es unknown
- 2013-11-07 CA CA2890643A patent/CA2890643C/en active Active
- 2013-11-07 ES ES13786679.4T patent/ES2628046T3/es active Active
- 2013-11-07 AU AU2013343550A patent/AU2013343550B2/en active Active
- 2013-11-07 EP EP13786679.4A patent/EP2917217B1/en active Active
- 2013-11-07 LT LTEP13786679.4T patent/LT2917217T/lt unknown
- 2013-11-07 PL PL13786679T patent/PL2917217T3/pl unknown
- 2013-11-07 HU HUE13786679A patent/HUE033485T2/en unknown
- 2013-11-07 PT PT137866794T patent/PT2917217T/pt unknown
- 2013-11-07 JP JP2015541140A patent/JP6101812B2/ja active Active
- 2013-11-07 KR KR1020157014733A patent/KR101812390B1/ko active Active
- 2013-11-07 RS RS20170565A patent/RS56056B1/sr unknown
- 2013-11-07 SM SM20170291T patent/SMT201700291T1/it unknown
- 2013-11-07 WO PCT/EP2013/073311 patent/WO2014072435A1/en active Application Filing
- 2013-11-07 US US14/441,785 patent/US9745299B2/en active Active
- 2013-11-07 BR BR112015010019-8A patent/BR112015010019B1/pt active IP Right Grant
- 2013-11-07 CN CN201380064124.XA patent/CN104903321B/zh active Active
- 2013-11-07 DK DK13786679.4T patent/DK2917217T3/en active
-
2015
- 2015-05-07 IL IL238693A patent/IL238693A0/en active IP Right Grant
-
2017
- 2017-05-29 HR HRP20170802TT patent/HRP20170802T1/hr unknown
- 2017-06-06 CY CY20171100592T patent/CY1119084T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2917217T3 (en) | 2017-06-19 |
| AU2013343550A1 (en) | 2015-05-14 |
| CN104903321A (zh) | 2015-09-09 |
| JP2016503408A (ja) | 2016-02-04 |
| RS56056B1 (sr) | 2017-09-29 |
| AU2013343550B2 (en) | 2016-09-22 |
| EP2917217A1 (en) | 2015-09-16 |
| CA2890643A1 (en) | 2014-05-15 |
| KR101812390B1 (ko) | 2017-12-26 |
| HRP20170802T1 (hr) | 2017-08-11 |
| US9745299B2 (en) | 2017-08-29 |
| PL2917217T3 (pl) | 2017-10-31 |
| SMT201700291T1 (it) | 2017-07-18 |
| WO2014072435A1 (en) | 2014-05-15 |
| US20150274726A1 (en) | 2015-10-01 |
| HUE033485T2 (en) | 2017-12-28 |
| KR20150091074A (ko) | 2015-08-07 |
| MX363609B (es) | 2019-03-28 |
| PT2917217T (pt) | 2017-06-07 |
| BR112015010019A2 (pt) | 2017-07-11 |
| MX2015005772A (es) | 2015-11-18 |
| CA2890643C (en) | 2018-05-22 |
| LT2917217T (lt) | 2017-07-25 |
| JP6101812B2 (ja) | 2017-03-22 |
| BR112015010019A8 (pt) | 2019-09-17 |
| IL238693A0 (en) | 2015-06-30 |
| GB201220157D0 (en) | 2012-12-26 |
| SI2917217T1 (sl) | 2017-08-31 |
| CN104903321B (zh) | 2017-10-24 |
| ES2628046T3 (es) | 2017-08-01 |
| EP2917217B1 (en) | 2017-03-08 |
| BR112015010019B1 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119084T1 (el) | Υποκατεστημενα τρικυκλικα βενζιμιδαζολια ως αναστολεις κινασης | |
| CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1120692T1 (el) | Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων | |
| CY1124793T1 (el) | Ακρυλαμιδια πυρρολο[2,3-d]πυριμιδινυλιου, πυρρολo[2,3-β]πυραζινυλιου και πυρρολο[2,3-d]πυριδινυλιου | |
| CY1123637T1 (el) | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| CY1123451T1 (el) | Αγωνιστες τριαζολης του υποδοχεα αρj | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1122247T1 (el) | Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3 | |
| CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| MX390537B (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm | |
| MX390348B (es) | Compuestos de benzimidazol como inhibidores de c-kit | |
| CY1119534T1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| CY1118874T1 (el) | Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1119714T1 (el) | Ενωσεις αναστολεων | |
| CY1117147T1 (el) | Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2 | |
| CY1118004T1 (el) | Αναστολεις cdk | |
| CY1122196T1 (el) | Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων |